C18orf51 Inhibitors
Divergent Protein Kinase Domain 1C (DPKD1C) is a protein that, by its name, suggests it belongs to the protein kinase superfamily, characterized by their enzymatic ability to transfer phosphate groups from high-energy donors, like ATP, to specific substrates. This process, known as phosphorylation, is a fundamental mechanism of signal transduction and regulation in cells, affecting various proteins' activity, interactions, and localization.The defining feature of protein kinases, including DPKD1C, is the kinase domain. This domain is highly conserved and is responsible for the enzyme's catalytic activity. The "divergent" descriptor in DPKD1C's name implies that its kinase domain may have unique structural features or substrate specificities that differ from the classical kinase domains, potentially adapting DPKD1C for specialized functions.
The "1C" designation could indicate that DPKD1C is a member of a larger family of related kinases, possibly with multiple isoforms or subtypes. These kinases often function in networks, where they are activated by upstream signals and, in turn, phosphorylate downstream targets, thereby propagating cellular responses to internal or external stimuli.Given the vast roles of protein kinases in cellular processes, DPKD1C might be involved in regulating cell growth, differentiation, metabolism, or apoptosis. Its unique divergent domain may confer specific functional roles, perhaps allowing it to participate in signaling pathways that are distinct from those of more conventional kinases.
SEE ALSO...
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Staurosporine | 62996-74-1 | sc-3510 sc-3510A sc-3510B | 100 µg 1 mg 5 mg | $82.00 $153.00 $396.00 | 113 | |
Staurosporine is a broad-spectrum kinase inhibitor. While not specific, it may indirectly affect DPKD1C activity by inhibiting related kinases or pathways. | ||||||
Rapamycin | 53123-88-9 | sc-3504 sc-3504A sc-3504B | 1 mg 5 mg 25 mg | $63.00 $158.00 $326.00 | 233 | |
Rapamycin inhibits mTOR, a key kinase in cell growth and proliferation. Indirect effects on DPKD1C could occur if it is involved in mTOR-related signaling pathways. | ||||||
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $123.00 $400.00 | 148 | |
LY294002 is a PI3K inhibitor. By inhibiting PI3K, this compound could indirectly influence DPKD1C if it is part of PI3K/Akt signaling pathways. | ||||||
SP600125 | 129-56-6 | sc-200635 sc-200635A | 10 mg 50 mg | $40.00 $150.00 | 257 | |
SP600125 is a JNK inhibitor. If DPKD1C is involved in pathways regulated by JNK, this inhibitor could indirectly affect its function. | ||||||
SB 203580 | 152121-47-6 | sc-3533 sc-3533A | 1 mg 5 mg | $90.00 $349.00 | 284 | |
SB203580 is a p38 MAPK inhibitor. If DPKD1C is involved in signaling pathways regulated by p38 MAPK, this inhibitor might indirectly influence its function. | ||||||
Dasatinib | 302962-49-8 | sc-358114 sc-358114A | 25 mg 1 g | $70.00 $145.00 | 51 | |
Dasatinib is a broad-spectrum tyrosine kinase inhibitor. It could indirectly affect DPKD1C if it has functional interactions with tyrosine kinase signaling pathways. | ||||||
Sorafenib | 284461-73-0 | sc-220125 sc-220125A sc-220125B | 5 mg 50 mg 500 mg | $57.00 $100.00 $250.00 | 129 | |
Sorafenib targets multiple kinases, particularly in the RAF/MEK/ERK pathway. Indirect modulation of DPKD1C could occur if it is involved in these pathways. | ||||||
Imatinib | 152459-95-5 | sc-267106 sc-267106A sc-267106B | 10 mg 100 mg 1 g | $26.00 $119.00 $213.00 | 27 | |
Imatinib selectively inhibits certain tyrosine kinases. It might have an indirect effect on DPKD1C if the protein interacts with or is regulated by these kinases. | ||||||
Bortezomib | 179324-69-7 | sc-217785 sc-217785A | 2.5 mg 25 mg | $135.00 $1085.00 | 115 | |
Bortezomib inhibits proteasome activity. If DPKD1C is regulated by ubiquitination or involved in proteasome-related pathways, this inhibitor could have an indirect effect. | ||||||
Lapatinib | 231277-92-2 | sc-353658 | 100 mg | $420.00 | 32 | |
Lapatinib inhibits EGFR and HER2 tyrosine kinases. It could indirectly influence DPKD1C activity if DPKD1C functions are connected with these kinases or their signaling pathways. | ||||||